Pulling SEC filings + quote and writing the call…

ICU MEDICAL INC/DE
Next earnings Aug 5, 2026 · consensus $1.93 EPS, $544M rev
Last earnings +2.9% on 2026-05-07
Deleveraging story with real cash flow, but razor-thin margins, tariff exposure and a 2030 debt wall keep this a hold.
Sources: SEC EDGAR (CIK 0000883984, latest 10-Q filed 2026-05-07) · EODHD · analysis by claude-code · as of 6/25/2026, 1:25:07 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Middling fundamentals and a rich price (~99% above fair value) leave little margin of safety — a wait-and-see.
ICU Medical is a mid-cap medical-device maker (infusion systems, IV consumables, critical care) that is mid-restructuring after the 2022 Smiths Medical acquisition saddled it with debt. FY2025 revenue of $2.23B fell 6.3% YoY — but that decline is partly explained by the April 2025 divestiture of the IV Solutions business to Otsuka, the proceeds of which funded a $200M Term Loan A prepayment. Total 2025 prepayments reached $290M, cutting long-term debt 17.4% to $1.27B and refinancing the rest through the October 2025 Amendment No. 2 (new $750M Term Loan A and $500M revolver, both maturing in 2030). Net income swung positive to $732K from a $118M loss — technically a turnaround, but a 0.0% net margin is not a thesis.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $1.32B | $2.28B | $2.26B | $2.38B | $2.23B |
| Gross profit | $491M | $698M | $740M | $825M | $822M |
| Operating income | $123M | -$42.9M | $22.8M | $43.0M | $42.8M |
| Net income | $103M | -$74.3M | -$29.7M | -$118M | $732K |
| Diluted EPS | $4.74 | -$3.11 | -$1.23 | -$4.83 | $0.03 |
| Net margin | 7.8% | -3.3% | -1.3% | -4.9% | 0.0% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Annual meeting vote results and bylaw amendments; routine governance update
Q1 2026 10-Q filed; details tariff cost trends and debt service post-refinancing
Q1 2026 10-Q filed; details tariff cost trends and debt service post-refinancing
2026 proxy statement; routine governance and exec comp disclosure
Officer/director change disclosed; leadership transition with no financial impact
FY25 10-K: IV Solutions divested, $290M debt paid down, $33.6M tariff hit
FY25 10-K: IV Solutions divested, $290M debt paid down, $33.6M tariff hit
Q3 2025 10-Q: post-IV Solutions divestiture period, debt prepayments continuing
Q3 2025 10-Q: post-IV Solutions divestiture period, debt prepayments continuing
Source: EODHD. Yield = trailing-12-month dividends ÷ price.
1049 tracked peers · median
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Last 90 days: 0 open-market buys · 3 sales
| 2026-05-22 | Woolson Daniel President | Sell | 2.12K @ $132.21 | $281K |
| 2026-05-14 | Sanzone Virginia Ruth VP, General Counsel | Sell | 2.45K @ $124.08 | $304K |
| 2026-05-13 | KENNEDY KOLLEEN T Director | Exercise | 1.25K | |
| 2026-05-13 | Hernandez Laurie Director | Exercise | 1.25K | |
| 2026-05-13 | FINNEY ELISHA W Director | Exercise | 1.25K | |
| 2026-05-13 | Abbey Donald Director | Exercise | 1.25K | |
| 2026-05-13 | Hoffmeister David F Director | Exercise | 1.25K | |
| 2026-05-13 | Greenberg David C. Director | Exercise | 1.25K | |
| 2026-05-12 | Greenberg David C. Director | Exercise | 2.42K @ $101.06 | $245K |
| 2026-05-12 | Greenberg David C. Director | Sell | 2.42K @ $122.91 | $298K |
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.